MedTrace Logo

A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

NCT05699239 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 326

Last updated 2025-02-28

No results posted yet for this study

Summary

A phase 2, randomized, placebo-controlled, double-blind, dose-finding study of TS-172 in hyperphosphatemia patients on hemodialysis

Conditions

  • Hyperphosphatemia Patients on Hemodialysis

Interventions

DRUG

TS-172 10mg bid

oral administration of TS-172 10 mg bid

DRUG

TS-172 30mg bid

oral administration of TS-172 30 mg bid

DRUG

TS-172 60mg bid

oral administration of TS-172 60 mg bid

DRUG

TS-172 20mg tid

oral administration of TS-172 20 mg tid

DRUG

Placebo

oral administration of placebo

Sponsors & Collaborators

  • Taisho Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Taisho Director · Taisho Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-08
Primary Completion
2023-12-26
Completion
2023-12-26

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05699239 on ClinicalTrials.gov